Columbia University researchers have discovered a previously unknown type of cell that helps lung tumors evade immune destruction. Published in Nature Immunology, the study found that certain fibroblasts — cells commonly found around solid tumors — express a gene called CHL1 that isn't normally present in healthy lung tissue. These CHL1 fibroblasts recruit regulatory T cells to the tumor's border using a signaling protein called CXCL9, effectively creating an immunosuppressive shield that protects the cancer.

In healthy lungs, regulatory T cells play a vital role in preventing runaway inflammation. But in the context of lung cancer, they end up doing the tumor a favor by keeping the immune system from mounting an attack. When researchers blocked the CXCL9 signaling pathway in mouse models, regulatory T cell accumulation dropped — and the immune system was able to target the tumor.

Key Takeaways:

• CHL1 fibroblasts are absent in healthy lungs, making them a potentially precise therapeutic target
• Patients with more CHL1 fibroblasts in their tumors showed reduced immune responses and lower progression-free survival
• Blocking the CXCL9 signaling axis could represent a novel immunotherapy strategy for lung cancer

Why it matters: Lung cancer is the leading cause of cancer-related death in the U.S., and new treatment angles are urgently needed. This discovery opens the door to therapies that could disarm a key tumor defense mechanism and enhance the immune system's ability to fight back.